Skip to main content
Premium Trial:

Request an Annual Quote

AB Sciex Mass Specs Used for Doping Detection at Winter Olympics

Premium

This story originally ran on Feb. 11.

AB Sciex mass spectrometers will be used to test for performance-enhancing drug use by athletes during the 2010 Winter Olympics, the company said this week.

Canada’s Institut Armand-Frappier, part of the country’s Institut National de la Recherché Scientifique, has created an $8.9 million testing facility to test for sports doping during the competition, which begins in Vancouver, BC, this weekend. As part of that effort, AB Sciex’s 4000 QTrap systems will be used to detect for stimulants, masking agents, glucocorticosteroids, and insulin.

Four of the LC-MS/MS platforms will be deployed, the company said in a statement.

Laura Lauman, a president of AB Sciex, said the agreement “is a great example of how mass spectrometry is increasingly being used to address a variety of scientific challenges beyond the research lab.”

AB Sciex, formed earlier this month from the former Applied Biosystems/MDS Analytical Technologies mass spec joint venture, operates within Danaher [see PM 02/05/10].

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.